Twitter
  • Business case
    • The migraine market
    • The market for rhinitis
    • Neuromodulation
    • Our patents
    • Our history
    • Partners
  • Clinical benefits
    • Migraine
    • Rhinitis
    • How Ozilia® is used
    • Positive indications – studies and publications
  • News
  • Investor relations
    • Press releases
    • Financial reports
    • The share
    • Company description
  • Svenska
  • Business case
    • The migraine market
    • The market for rhinitis
    • Neuromodulation
    • Our patents
    • Our history
    • Partners
  • Clinical benefits
    • Migraine
    • Rhinitis
    • How Ozilia® is used
    • Positive indications – studies and publications
  • News
  • Investor relations
    • Press releases
    • Financial reports
    • The share
    • Company description
  • Svenska

Category: Uncategorized

  • Uncategorized

    Biostock summary of 2023: “Chordate continues its marketing activities and exit strategy”

  • Uncategorized

    First patients included in Chordate Medical’s Post-Market Study PM010

  • Uncategorized

    Record Attendance for Chordate Medical at Congress – “Significant Buying Interest from Several Markets”

  • Uncategorized

    Biostock interview: Chordate’s CSO comments on the start of the PM009 study

  • Uncategorized

    Chordate Medical exhibits at the European Headache Congress in Barcelona

  • Uncategorized

    First patient included in Chordate Medical’s pilot study PM009

  • Uncategorized

    Chordate’s CEO on client visits in the Gulf region: “A growing market with great potential for Ozilia”

  • Uncategorized

    Biostock interview: Anders Weilandt on the breakthrough in Germany and launch in the United Arab Emirates

  • Uncategorized

    Chordate Medical launches Ozilia migraine and rhinitis treatment in the United Arab Emirates

  • Uncategorized

    Chordate Medical receives its first installation of the Ozilia migraine treatment at a private clinic in Hamburg

1 … 6 7 8 9 10 … 19

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia®, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East.

Press releases

Chordate’s application for delisting has been approved

18 February 2026

Chordate applies for delisting

18 February 2026

Chordate announces updated timetable for delisting

16 January 2026

Chordate Medical AB

Färögatan 33
SE-164 51 Kista
Sweden
For visits: floor B31

Delivery: Hanstavägen 31, 164 53 Kista

Privacy policy

Twitter
Manage Cookie Consent
We use cookies on our website to provide you with the most relevant experience and personalize ads by remembering your preferences on repeat visits. By clicking "Accept all" you agree to the use of all cookies. You can also visit "Cookie Settings" to provide controlled consent.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}